Journal article

Immune Infiltration in Invasive Lobular Breast Cancer

Christine Desmedt, Roberto Salgado, Marco Fornili, Giancarlo Pruneri, Gert Van den Eynden, Gabriele Zoppoli, Francoise Rothe, Laurence Buisseret, Soizic Garaud, Karen Willard-Gallo, David Brown, Yacine Bareche, Ghizlane Rouas, Christine Galant, Francois Bertucci, Sherene Loi, Giuseppe Viale, Angelo Di Leo, Andrew R Green, Ian O Ellis Show all

Journal of the National Cancer Institute | OXFORD UNIV PRESS INC | Published : 2018

Abstract

Background: Invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal cancer (IDC). Here, we aimed at evaluating the prevalence, levels, and composition of tumor-infiltrating lymphocytes (TILs) and their association with clinico-pathological and outcome variables in ILC, and to compare them with IDC. Methods: We considered two patient series with TIL data: a multicentric retrospective series (n = 614) and the BIG 02-98 study (n = 149 ILC and 807 IDC). We compared immune subsets identified by immuno-histochemistry in the ILC (n = 159) and IDC (n = 468) patients from the Nottingham series, as well as the CIBERSORT immune profilin..

View full abstract

Grants

Funding Acknowledgements

This work was supported by Susan Komen for the Cure, Fondation MEDIC, Les Amis de Bordet (CD), Fonds National de Recherche Scientifique (DB and CS), the Cancer Council Victoria John Colebatch fellowship (SL), the Breast Cancer Research Foundation, the Italian Association for Leukemia and Lymphoma, and the Italian Association for Cancer Research. We thank the Nottingham Health Science Biobank and Breast Cancer Now Tissue Bank, as well as the bio-banks from the Institut Jules Bordet, the European Institute of Oncology, the Sint Augustinus Hospital, the Cliniques Universitaires de Saint Luc, and the Institut Paoli-Calmettes for the provision of tissue samples. BIG 2-98 was conducted under the umbrella of the Breast International Group, with sponsorship and funding provided by Sanofi.